Cargando…
Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
Autores principales: | Nabavi, Seyed Fazel, Habtemariam, Solomon, Clementi, Emilio, Berindan-Neagoe, Ioana, Cismaru, Cosmin Andrei, Rasekhian, Mahsa, Banach, Maciej, Izadi, Morteza, Bagheri, Mahdi, Bagheri, Mohammad Sadegh, Nabavi, Seyed Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212214/ https://www.ncbi.nlm.nih.gov/pubmed/32399097 http://dx.doi.org/10.5114/aoms.2020.94504 |
Ejemplares similares
-
Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?
por: Nabavi, Seyed Fazel, et al.
Publicado: (2020) -
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
por: Habtemariam, Solomon, et al.
Publicado: (2020) -
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
por: Habtemariam, Solomon, et al.
Publicado: (2020) -
Rationale for Effective Prophylaxis Against COVID‐19 Through Simultaneous Blockade of Both Endosomal and Non‐Endosomal SARS‐CoV‐2 Entry into Host Cell
por: Nabavi, Seyed Fazel, et al.
Publicado: (2021) -
Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID‐19: Shoot the messenger!
por: Habtemariam, Solomon, et al.
Publicado: (2020)